Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: QS stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs Revenue / share.
Implied fair value · at QS's multiple
Needs QS P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: QS FY 2025 (ended Dec 31, 2025) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / EBITDA 0.99x
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
CTXR carries the larger enterprise value at -$31.69M against -$425.39M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 0.99x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
QUANTUMSCAPE CORPORATION · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.02x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
2.21x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$970.81M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Microvast Holdings, Inc.
QS vs MVST
Fluence Energy, Inc.
QS vs FLNC
Enovix Corp
QS vs ENVX
APPLIED MATERIALS INC /DE
QS vs AMAT
Zomedica Corp.
QS vs ZOM
Aquestive Therapeutics, Inc.
QS vs AQST
ACADIA PHARMACEUTICALS INC
QS vs ACAD
AMGEN INC
QS vs AMGN
GILEAD SCIENCES, INC.
QS vs GILD
AbbVie Inc.
QS vs ABBV
$22.36M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
